AusBiotech launches ASX feed


A life science-specific Australian Stock Exchange (ASX) data feed has been launched on AusBiotech’s website to increase the profile of and investment in Australia’s biotechnology companies.

As part of AusBiotech’s investment attraction programme, an ASX feed tracking the 178 ASX-listed biotechnology and pharmaceutical companies has been established.

The ASX feed, updated daily, lists stock price and key metrics such as latest price, earnings per share (EPS), and year return. The AusBiotech website homepage also includes a scrolling banner with the top 50 (by percentage change) ASX ticker information and stock prices.

AusBioStocks data (August 2023) revealed the 178 ASX-listed life science companies reported a market capitalisation of $231 billion. In contrast, the 161 ASX-listed life science companies were worth approximately $170 billion in 2019 highlighting the life science sector’s growing economic contribution to the Australian economy.

Data also shows 8.5 per cent of listed companies have a market cap of more than $1 billion, while 31 pe rcent of companies are worth more than $100 million. Identified in AusBiotech’s Biotechnology Blueprint decadal strategy, the market cap is one quantifiable measure of the life science sector’s economic contribution to the Australian economy, and the proportion of biotech companies achieving market valuations greater than $100 million measures the industry’s ability to create companies of significant future value.

AusBiotech invites qualified investors, including venture capital firms, private equity investors, high-net-worth individuals, research analysts, brokers, family offices, to access their complimentary registration to attend the inaugural AusMedtechInvest event at the Adelaide Convention Centre on 21 May, providing them with a valuable opportunity to make meaningful connections with both private and listed companies, hear the latest market updates, and explore potential investment prospects. Investors can also access a free pass to Day One of AusMedtech 2024 to attend the Early-Stage Innovation Forum rapid-fire pitch competition where emerging pre-seed and Series A medical technologies are pitched to a panel of industry experts. Find out more and register here.

As Australia’s largest national life sciences member organisation, AusBiotech seeks to demonstrate the value of the sector to investors, and develops, gathers, tracks, and promotes industry knowledge and data, to inform the industry’s competitive advantage.

Review the AusBiotech ASX-feed here, and order the list by code or percentage change.